Formamide

Formamide

SCHEMBL5161701

NC=O.NCCOC(c1ccccc1)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.48
SLC6A4 P31645 2/20 0.48
SLC6A3 Q01959 2/20 0.48
KCNK2 O95069 1/20 0.48
KCNH2 Q12809 1/20 0.48
CACNA1C Q13936 1/20 0.48
FFAR1 O14842 1/20 0.47
SLC7A5 Q01650 4/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
GPR55 Q9Y2T6 1/20 0.45
IDO1 P14902 2/20 0.44
TDO2 P48775 2/20 0.44
ACP3 P15309 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
ALOX15 P16050 1/20 0.43
SLC6A1 P30531 1/20 0.43
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160316 0.94 SLC6A2 (0.52) SLC6A2SLC6A4SLC6A3KCNK2KCNH2
SCHEMBL4667595 0.85 FFAR1 (0.52) SLC6A2SLC6A4SLC6A3KCNK2KCNH2
SCHEMBL7288351 0.79 SCN1A (0.57) SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL4667558 0.79 FFAR1 (0.48) SLC6A2SLC6A4SLC6A3KCNH2FFAR1
Formamide SCHEMBL5161694 0.75 MEN1 (0.46) SLC6A2SLC6A4SLC6A3KCNK2KCNH2
Bromomethane SCHEMBL5569429 0.74 SLC6A2 (0.56) SLC6A2SLC6A4SLC6A3KCNH2
Maleic Acid SCHEMBL9771017 0.74 KDM4E (0.50)
SCHEMBL11054725 0.72 ACP3 (0.53) SLC6A2SLC6A4SLC6A3KCNK2KCNH2
SCHEMBL5163408 0.72 ACP3 (0.43) SLC6A2SLC6A4SLC6A3KCNK2KCNH2
SCHEMBL5161949 0.72 HRH1 (0.67) SLC6A2SLC6A4SLC6A3KCNK2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1790337-A2 Methods and compounds for treating depression and other disorders NPS PHARMACEUTICALS, INC. (US) 2007-05-30 EP disclosed
EP-1096926-B1 METHODS AND COMPOUNDS FOR TREATING DEPRESSION NPS PHARMA INC (US) 2007-02-28 EP disclosed
US-20040039014-A1 Methods and compounds for treating depression and other disorders NPS PHARMACEUTICALS, INC. 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039014-A1 Methods and compounds for treating depression and other disorders GRIN1, GRIN2C, GRIN3B SLC6A2 89/4885SLC6A4 24/4885SLC6A3 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.